Oppenheimer Asset Management Inc. Buys Shares of 1,289 Krystal Biotech, Inc. (NASDAQ:KRYS)

Oppenheimer Asset Management Inc. purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,289 shares of the company’s stock, valued at approximately $235,000.

Several other hedge funds and other institutional investors have also made changes to their positions in KRYS. GAMMA Investing LLC raised its position in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after acquiring an additional 93 shares during the last quarter. Jamison Private Wealth Management Inc. purchased a new stake in Krystal Biotech in the 2nd quarter valued at approximately $28,000. Key Financial Inc acquired a new stake in Krystal Biotech during the 2nd quarter valued at $28,000. Blue Trust Inc. increased its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after buying an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in shares of Krystal Biotech in the third quarter worth $53,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now owns 1,500,882 shares in the company, valued at $296,814,424.32. This trade represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 14.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Stifel Nicolaus lifted their price objective on Krystal Biotech from $204.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research note on Tuesday, November 5th. Chardan Capital lifted their target price on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. William Blair upgraded Krystal Biotech to a “strong-buy” rating in a report on Friday, August 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $202.29.

Krystal Biotech Trading Up 0.1 %

KRYS stock opened at $178.10 on Thursday. The company has a market cap of $5.12 billion, a PE ratio of 100.48 and a beta of 0.82. The stock has a 50-day moving average price of $180.45 and a two-hundred day moving average price of $182.02. Krystal Biotech, Inc. has a 12-month low of $99.00 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 4th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The company’s revenue was up 879.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.67) EPS. Equities analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).